Charles River Laboratories’ announcement of a planned leadership transition marks one of the most consequential succession moments in the global pr...
Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and China New...
— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease — HUTCHMED (China) Lim...
International medical technology and cybersecurity company Sectra (STO: SECT B), in collaboration with distribution partner Matsunami Glass has comm...
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for...
MDR-001 progressed from program discovery to Phase III in just 4.5 years, much faster than traditional development cycles. Phase IIb data demonstrated...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) announced that its TROP2-directed antibody-drug ...
Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ® BYOOVIZ becomes the fourth biosimi...
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its Adalimumab Injection 9MW01...
Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Grou...
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of...
PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and fibroste...
Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-inte...
NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular ...
© 2026 Biopharma Boardroom. All Rights Reserved.
